Susoctocog alfa

Susoctocog alfa is a recombinant factor VIII (FVIII) product used in the treatment of Hemophilia A. It is a blood-clotting protein that is genetically engineered to help prevent bleeding episodes in people with Hemophilia A.

Overview

Susoctocog alfa, also known as Obizur, is a recombinant porcine sequence factor VIII. It is used for the treatment of bleeding episodes in patients with acquired hemophilia A, a rare and potentially life-threatening bleeding disorder caused by the development of antibodies (inhibitors) against endogenous factor VIII.

Mechanism of Action

Susoctocog alfa works by replacing the missing factor VIII, a protein necessary for blood clotting. This helps to prevent prolonged bleeding episodes. The porcine sequence of susoctocog alfa is similar enough to human factor VIII to have a therapeutic effect, but different enough to be less likely to be affected by the inhibitors that cause acquired hemophilia A.

Usage

Susoctocog alfa is administered intravenously. The dosage and duration of treatment depend on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient's clinical condition.

Side Effects

Common side effects of susoctocog alfa include development of antibodies against the medication, which may reduce its effectiveness. Other side effects may include dizziness, fever, and discomfort or irritation at the injection site.

See Also

• Hemophilia
• Factor VIII
• Blood clotting

References

• FDA approval of Obizur for the treatment of acquired hemophilia A. FDA News Release. October 28, 2014.
• EMA assessment report for Obizur. EMA/CHMP/573766/2014. October 23, 2014.